Bio-Works Technologies (BIOWKS) investor relations material

Executive summary

• Net sales rose to 29.3 MSEK in Q1 2026 from 9.0 MSEK in Q1 2025, driven by large European deliveries.

• Operating profit reached 4.2 MSEK, a turnaround from a -7.8 MSEK loss year-over-year.

• Profit for the quarter was 4.7 MSEK, compared to a loss of -8.0 MSEK in the prior year.

• Cash flow improved to +6.3 MSEK from -4.4 MSEK, with cash and equivalents at 41.3 MSEK.

• Order intake decreased to 15.5 MSEK from 31.6 MSEK, reflecting variability in large customer orders.

Financial highlights

• Gross margin remained high, supporting operational leverage and profitability.

• Personnel costs increased to 9.0 MSEK due to new hires and higher employment rates.

• Other external costs rose to 8.5 MSEK, mainly from increased sales activities.

• Earnings per share before dilution were +0.05 SEK, after dilution +0.04 SEK (vs. -0.10 and -0.09 SEK, respectively, last year).

Outlook and guidance

• Focus remains on expanding global presence, increasing large customer base, and maintaining cost discipline.

• Strategy aims for sustainable profitable growth by deepening customer relationships and recurring business.